PharmaGraphX

Log in Get Started

Evolocumab

Repatha

Uncategorized

Standard

Half-life

11-17 days

Protein Binding

N/A

Metabolized By

N/A

External

Drugs.com

Mechanism of action

Monoclonal antibody that binds PCSK9, increasing LDL receptor recycling

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Dyslipidemia, Hypercholesterolemia
·Pancreatic Ductal Adenocarcinoma
·Pancreatic Cancer
·Pancreas Cancer
·Metastatic Cancer

Interactions

No curated interaction pairs are recorded for Evolocumab. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Injection site reactions
Nasopharyngitis
Back pain

Pharmacokinetics

Half-life: 11-17 days
Protein binding: N/A

Pregnancy & lactation

Not recorded for Evolocumab. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement